In vivo and in vitro trimethadione oxidation activity of the liver from various animal species including mouse,hamster,rat,rabbit,dog,monkey and human

Abstract

Trimethadione (TMO) has the properties required of a probe drug for the evaluation of hepatic drug-oxidizing capacity and, in this study, we have summarized the in vivo and in vitro metabolism of TMO in various animal species including mouse, hamster, rat, rabbit, dog, monkey and human. In the in vivo study, the plasma TMO level was measured after intravenous or oral (human) administration of TMO at a dose of 4 mg/kg to various animal species. The rate of TMO metabolic clearance in these animal species in vivo was in the order mouse > hamster >rat>rabbit>dog>monkey>human. In the in vitro study, species differences were observed in the cytochrome P450 (P450) content and drug-oxidizing enzyme activity. The content of P450 was monkey> mouse>dog>rabbit>hamster>rat>human. On the other hand, TMO N-demethylation was in the order mouse >hamster >rat >rabbit>dog>monkey>human. There was a good correlation between the mean total body clearance of TMO (in vivo)andthemeanTMON-demethylase activity (in vitro) (y=1.7×+0.11, r=0.965, P<0.001).

These results show that TMO is a probe agent with metabolic and pharmacokinetic characteristics making it attractive for the in vivo and in vitro characterization of metabolic activity in various animal species.

Keywords

trimethadione dimethadione probe drug hepatic oxidizing capacity cytochrome P450 liver function test pharmacokinetic study species

References

Gibson GG , Skett P. Chapter 4. Factors affecting drug metabolism: internal factors, In: Introduction to Drug Metabolism, Gibson GG , Skett P. (ed) (2nd edition), Blackie Academic & Professional, London : 1994; pp.107-110.

Tanaka E , Kinoshita H , Yoshida T , Kuroiwa Y. Relationship between trimethadione metabolism and hepatic drug-oxydizing enzyme activities in different animal species . Journal of Pharmacobio-Dynamics 1983; 6: 481-486 .

Imai Y , Ito A , Sato R. Evidence for biochemically different type of vesicles in the hepatic microsomal function . Journal of Biochemistry 1966; 60: 417-438 .

Tanaka E , Misawa S. Simultaneous determination of serum trimethadione and its metabolite by gas chromatography . Journal of Chromatography Biomedical Application 1987; 413: 376-378 .

Omura T , Sato R. The carbon monoxide binding pigment of liver microsomes, I. Evidence for its hemoprotein nature . Journal of Biological Chemistry 1964; 239: 2370-2378 .

Lowry OH , Rosebrough NJ , Farr AL , Randall RJ Protein measurement with Folin phenol reagent . Journal of Biological Chemistry 1951; 193: 265-275 .

Nakamura M et al. Trimethadione metabolism, a useful indicator for assessing hepatic drug-oxidizing capacity . Biochemical Pharmacology 1944; 47: 247-251 .

Kurata N et al. Estimation of the human hepatic microsomal cytochrome P-450 species responsible to the trimethadione metabolism . Japanese Journal of Pharmacology 1997; 73(Suppl.1): 115P-115P .

Tanaka E et al. Simplified approach for determination of hepatic drug-oxidizing capacity using trimethadione metabolism as an indicator . Biopharmaceutics and Drug Disposition 1989; 10: 617-620 .

10.

Withrow CD. Trimethadione. In: Antiepileptic Drugs, Woodbury DM , Penry JK , Pippenger CE. (eds) (2nd edition) Raven Press, New York : 1982; pp.681-695.

11.

Branch RA. Drugs as indicators of hepatic function . Hepatology 1982; 2: 97-105 .

12.

Park BK. Assessment of the drug metabolism capacity of the liver . British Journal of Clinical Pharmacology 1982; 14: 631-651 .

13.

Tanaka E et al. Trimethadione metabolism as a probe drug to estimate hepatic oxidizing capacity in rats . Comparative Biochemistry and Physiology 1993; 104C: 205-207 .

14.

Tanaka E et al. Trimethadione tolerance test for evaluation of functional reserve of the liver in patients with liver cirrhosis and esophageal varices . Journal of Pharmacobio-Dynamics 1986; 9: 297-302 .

15.

Tanaka E et al. Trimethadione metabolism in patients with normal liver and in patients with chronic liver disease . Journal of Pharmacobio-Dynamics 1987; 10: 499-502 .

16.

Tanaka E et al. Trimethadione tolerance test for one-point estimation of the severity of liver damage in cirrhotic patients . International Journal of Clinical Pharmacology Therapy and Toxicology 1991a; 29: 333-336 .

17.

Tanaka E et al. The impact of liver cirrhosis and chlelithiasis on Phase I and II reactions using antipyrine and trimethadione as a model substrate . Japanese Journal of Clinical Pharmacology and Therapeutics 1991b; 22: 635-639 .

18.

Tanaka E et al. A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites . International Journal of Clinical Pharmacology Therapy and Toxicology 1992; 30: 336-341 .

19.

Tanaka E et al. Effect of cigarette on caffeine and trimethadione N-demethylation catalyzed by different cytochrome P450 isozymes in patients with cirrhisis . International Hepatology Communications 1994; 2: 341-346 .

20.

Abei M et al. Clinical significance of the trimethadione tolerance test in chronic hepatitis: A useful indicator of hepatic drug metabolizing capacity . Journal of Gastroenterology 1995; 30: 478-484 .

21.

Kato R. Characteristics and differences in the hepatic mixed function oxidases of different species . Pharmacolgy and Therapeutics 1979; 6: 41-98 .

22.

Amri HS , Batt AM , Siest G. Comparison of cytochrome P-450 content and activities in liver microsomes of seven animal species, including man . Xenobiotica 1986; 16: 351-358 .

23.

Shimada T et al. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans . Archives of Toxcology 1977; 71: 401-408 .

24.

Bayliss MK , Bell JA , Wilson K , Park GR. 7- Ethoxycoumarin O-deethylase kinetics in isolated rat, dog and human hepatocyte suspensions . Xenobiotica 1994; 24: 231-241 .

25.

Kato R , Yamazoe Y. The importance of substrate concentration in determining cytochrome P450 therapeutically relevant in vivo . Pharmacogenetics 1994; 4: 359-362 .

26.

Yamazaki H et al. 7- Ethoxycoumarin O-deethylation catalyzed by cytochrome P-450 1A2 and 2E1 in human liver microsomes . Biochemical Pharmacology 1996; 51: 313-319 .